

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32

Correlation of Suspected COVID-19 Symptoms with COVID-19 Positivity in Children

Sanika A. Satoskar⁴, MPH, Daniel Hindman^{1,2*}, MD, MPH, Aamna Husain¹, DO, Laura Prichett³, PhD, MHS, Oluwakemi B. Badaki¹, MD, PhD, Ann Kane^{1*}, MD

¹Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD, USA

²Department of Internal Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA

³Biostatistics, Epidemiology, and Data Management (BEAD) Core, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, MD, USA

⁴Northeast Ohio Medical University, Rootstown, OH, USA

*** Correspondence:**

Ann Kane

annkane@jhu.edu

Daniel Hindman

dhindma1@jhu.edu

Keywords: COVID-19, Pediatrics, Emergency Medicine, Infectious Diseases, Epidemiology

Word Count: 2,053

Number of tables: 2

Correlation of Suspected COVID-19 Symptoms with COVID-19 Positivity in Children

33 **Abstract**

34 Background: Early in the pandemic, COVID-19 was found to infect adults at higher rates than
35 children, leaving limited data on disease presentation in children. Further understanding of the
36 epidemiology of COVID-19 symptoms among children is needed. Our aim was to explore how
37 symptoms vary between children testing positive for COVID-19 infection versus children testing
38 negative.

39 Methods: Data analysis of symptom prevalence among pediatric patients presenting to emergency
40 departments (ED) in the Johns Hopkins Health System (JHHS) with concern for COVID-19 who
41 subsequently received COVID-19 testing. Inclusion criteria included patients 0-17 years-of-age, ED
42 evaluation between March 15th, 2020 - May 11th, 2020, and those who were ordered for COVID-19
43 testing. Chart review was performed to document symptoms using ED provider notes. Comparisons
44 were made using chi-squared t-tests and Student's t-tests.

45 Results: Fever (62.6%) and cough (47.9%) were the most prevalent symptoms among children with
46 suspected COVID-19 infection. Compared to children with a negative COVID-19 test, children who
47 tested positive had higher prevalence of myalgia (21.7% vs 6.0%) and loss of taste/smell (15.2% vs
48 0.9%). Over half of the children who tested positive for COVID-19 had public insurance (52.2%) and
49 58.7% of the positive tests occurred among children with Hispanic ethnicity.

50 Conclusions: Myalgia and loss of taste/smell were found to be significantly more prevalent among
51 COVID-19 positive children compared to children testing negative. Additionally, children with
52 public insurance and those with Hispanic ethnicity were more likely to test positive, emphasizing the
53 importance of social factors in the screening and decision-making process.

54

55

56

57

58

59

60

61

62

63

64

65

66

Correlation of Suspected COVID-19 Symptoms with COVID-19 Positivity in Children

67 1 Introduction

68 COVID-19 has had widespread effects across the United States (US), including over
69 70,000,000 cases diagnosed and over 850,000 deaths since the start of the pandemic, as of January
70 26, 2022 [1]. Early in the pandemic, SARS-CoV-2 was found to infect adults at a much higher rate
71 with more severe manifestations compared to children (0-17 years old) [2-4]. As a result, initial
72 research efforts to understand COVID-19 were focused largely on the adult population, leaving very
73 limited data on disease epidemiology among children.

74 Recent data shows that COVID-19 infection may present differently in children compared to
75 adults, as seen by differences in the timing of symptom presentation and disease severity [3-6]. It is,
76 therefore, plausible that the prevalence of certain symptoms will vary in the pediatric population
77 compared to adults. Further understanding of the epidemiology of symptoms among children is
78 necessary for guiding decisions regarding testing.

79 Although many children have asymptomatic infections [6], studies show that children with
80 symptomatic SARS-CoV-2 infections develop symptoms that range in severity across multiple organ
81 systems. These symptoms have been shown to primarily affect the respiratory system, and include
82 cough, sore throat, and shortness of breath [7]. Gastrointestinal (GI) symptoms are also common and
83 include diarrhea and vomiting. Recent evidence shows that the Multisystem Inflammatory Syndrome
84 (MIS-C), a serious condition resulting in systemic inflammation that adversely affects the heart [8],
85 lungs, kidneys and GI organs, is also associated with COVID-19 in children [9-11].

86 However, an analysis to further explore the association between individual symptoms with
87 COVID-19 test positivity has not been performed in children. Assessing whether certain symptoms
88 are more specific for a positive COVID-19 test has utility to the clinical provider, providing a gauge
89 that helps to discern whether any particular symptom is likely to place a patient in one of two groups:
90 COVID-19 illness or not COVID-19 illness. This is crucial as it can help aid in risk stratification and
91 efficient utilization of testing resources in children, which is critical to pandemic control [12-13]
92 especially when resources are scarce, as was evident during the early months of the pandemic.

93 Given the varying presentations of pediatric COVID-19 illness, we conducted an analysis of
94 symptom prevalence among pediatric patients presenting to emergency departments with concern for
95 COVID-19 who subsequently received COVID-19 testing. We collected data from three pediatric
96 emergency department (ED) facilities in a single health system during the initial stages of the
97 pandemic. Our primary specific aim was to explore how symptoms vary between children testing
98 positive for COVID-19 infection versus children testing negative, which was used to associate
99 individual symptoms to COVID-19 test positivity.

100 2 Methods

101 2.1 Design and Sample:

102 We performed a retrospective secondary data analysis of children from 0 through 17 years of
103 age who presented with possible COVID-19 disease to three Pediatric ED facilities in a single health
104 system – two suburban community-based hospitals (PED 2, PED 3) and an urban designated level 1
105 pediatric trauma center (PED 1). Relevant encounters took place between March 15th, 2020 and May
106 11th, 2020. We included any patient who was ordered for COVID-19 testing during the time period.
107 COVID-19 testing was ordered based on if the patient met the testing algorithm criteria set at the

Correlation of Suspected COVID-19 Symptoms with COVID-19 Positivity in Children

108 time, and this algorithm changed over the study period as the pandemic evolved. SARS-CoV-2
109 testing was performed using a PCR assay. Molecular assays used for diagnosis at the time included
110 Xpert Xpress SARS-CoV-2/Flu/RSV (Cepheid), NeuMoDx SARS-CoV-2 (Qiagen), Cobas SARS-
111 CoV-2 (Roche), ePlex Respiratory Pathogen Panel 2 (Roche), Aptima SARS-CoV-2 (Hologic),
112 Accula SARS-CoV-2 assays (ThermoFisher Scientific), and RealStar® SARS-CoV-2 RT-PCR
113 (Altona Diagnostics) [14-17]. Choice of test method was based on what was optimal for fastest result
114 turnaround time given the staffing during the shift and test volumes. ED visits that were transfers
115 from one of the other two facilities were excluded. This study was approved by the Johns Hopkins
116 University Institutional Review Board (IRB00246826).

117 **2.2 Data Source:**

118 We utilized data collected via a Precision Medicine Analytics Data Commons Platform
119 (PMAP) based on electronic medical records (EMR) [18]. Relevant variables included the date of the
120 visit, the associated pediatric emergency department, vital signs, and patient demographics, including
121 age, sex, race, ethnicity, and insurance. We also included receipt of SARS-CoV-2 testing, results of
122 SARS-CoV-2 testing, isolation orders, acuity measured with the emergency severity index (ESI),
123 presence of influenza-like illness (ILI) symptoms, and the patient's area deprivation index (ADI)
124 based on the census block.

125 For every encounter where SARS-CoV-2 testing was obtained, we performed chart review
126 based on a pre-determined protocol to document the presence or absence of symptoms using provider
127 notes in the ED. Pertinent symptoms included fever, headache, sore throat, cough, shortness of
128 breath, myalgias, diarrhea, and loss of taste or smell. We used REDCap for data entry. All charts that
129 were flagged for questions were reviewed by a single senior investigator to resolve any ambiguity.
130 Missing data were not imputed, however there were very little missing data. Out of the total 516
131 patients, 18 patients had missing data for some of the variables and these patients were excluded from
132 the analysis involving those variables.

133 **2.3 Data Analysis:**

134 We analyzed data using Microsoft Excel for Mac 2021 and StataIC 16.1 (StataCorp. 2019.
135 *Stata Statistical Software: Release 16*. College Station, TX: StataCorp LLC). The prevalence of each
136 pertinent symptom was found by dividing the number of children presenting to the ED with that
137 symptom over the total ED visits in our cohort during that time period. The prevalence rate of each
138 symptom was then compared between children who tested positive for SARS-CoV-2 to those who
139 tested negative for SARS-CoV-2. Subjective parameters including myalgias, headaches, and loss of
140 taste or smell were analyzed by a subgroup analysis which included only children above 5 years-of-
141 age. We made comparisons using chi-squared t-tests for categorical variables and Student's t tests for
142 continuous variables.

143 **3 Results**

144 We identified 516 patient encounters where providers were concerned for possible COVID-19
145 and subsequently tested for SARS-CoV-2. There were 46 (8.9%) children who tested positive for
146 SARS-CoV-2 and 470 (91.1%) who tested negative. **Table 1** presents summary descriptive
147 characteristics of the study population.

Correlation of Suspected COVID-19 Symptoms with COVID-19 Positivity in Children

148 The majority of COVID-19 cases occurred in the 12-17 years age group (47.8%). The mean
149 age among those who tested positive was 8.76 years compared to 6.64 years among those who were
150 negative ($p = 0.01$). Although the majority of our study population consisted of non-Hispanics
151 (78.5%), 58.7% of positive tests occurred among children with Hispanic ethnicity. The majority of
152 children who tested negative for SARS-CoV-2 were either non-Hispanic Black (35.1%) or non-
153 Hispanic White (30.4%). Over half of the children who tested positive for SARS-CoV-2 had public
154 health insurance (52.2%).

155 Fever (62.6%) and cough (47.9%) were the most prevalent symptoms among children
156 suspected of SARS-CoV-2. When compared to children with a negative SARS-CoV-2 test, children
157 who tested positive had a significantly higher prevalence of myalgia (21.7% vs 6.0%, p -value =
158 0.001) and loss of taste or smell (15.2% vs 0.9%, p -value < 0.001), as summarized in **Table 2**. There
159 were no significant differences in the prevalence of sore throat, cough, shortness of breath, and
160 diarrhea symptoms between children testing positive versus negative for SARS-CoV-2.

161 **4 Discussion**

162 In this retrospective secondary data analysis utilizing EMR data and chart review, we found
163 that among children who present with suspected COVID-19 infection, fever and cough are the most
164 prevalent symptoms. However, we find that symptoms of myalgia and loss of taste or smell are
165 associated with COVID-19 positivity in our pediatric patient population.

166 Although many studies have documented a variety of symptoms, including these [6-7], fever
167 and cough have been reported as two predominant symptoms associated with SARS-CoV-2 infection
168 in children [7-8]. Fever and cough were also found to be present in the majority of children who
169 underwent testing for COVID-19 infection in our study. However, interestingly, it was myalgia and
170 loss of taste or smell that were significantly associated with a positive COVID-19 test result. Myalgia
171 symptoms have been implicated in many inflammatory conditions [9]. It may be possible that in
172 children suspected of COVID-19 infection, myalgia may be a direct manifestation of the systemic
173 inflammatory state implicated in COVID-19 pathogenesis, and therefore a more specific indicator for
174 positive COVID-19 infection compared to other viral respiratory symptoms alone.

175 Our study took place during the early months of the pandemic, when testing resources were
176 scarce and limited, and as a result resource allocation and utilization had to be done prudently.
177 Currently, COVID-19 infection rates are increasing in the pediatric population [19-20], and several
178 health systems are starting to face similar testing resource shortages as was evident early in the
179 pandemic [21]. Our study identifies symptoms that are most specific for SARS-CoV-2 positivity in
180 our pediatric study population, which is essential to aid in strengthening COVID-19 test specificity to
181 aid in efficient resource utilization.

182 In our study population, racial and socioeconomic factors had a strong association with
183 SARS-CoV-2 positivity. Children who had public insurance or no insurance were significantly more
184 likely to test positive for SARS-CoV-2 compared to children with private insurance. Additionally, we
185 found ethnicity to be significantly associated with SARS-CoV-2 positivity where Hispanic children
186 had a higher likelihood of testing positive compared to non-Hispanic children. Although this
187 phenomenon has been documented in adults, our study provides further insight among the pediatric
188 population. This is especially crucial since the urban hospitals under the Johns Hopkins Health
189 System (JHHS) predominantly serve Black and Hispanic populations, mainly from within and
190 surrounding the Baltimore area. Interestingly in our study, most of our study population consisted of

Correlation of Suspected COVID-19 Symptoms with COVID-19 Positivity in Children

191 non-Hispanic children, however over half of the positive tests occurred in Hispanic children. It has
192 been extensively documented that many children belonging to minority racial and ethnic groups
193 reside in poorer neighborhoods with significantly lower resources [22-24]. These children often live
194 in high-density overcrowded housing, are more reliant on public transportation, and lack preventive
195 health services, all of which may impact their ability to adhere to social distancing guidelines and
196 subsequently increase their susceptibility to COVID-19 exposure [25-26]. Although the increased
197 COVID-19 positivity rates that were observed in Hispanics and in patients with public or no
198 insurance in our study could be in part due to the sociodemographic structure of the surrounding
199 areas, several studies have shown that minority racial groups and those belonging to lower
200 socioeconomic statuses were at increased risk for serious and fatal COVID-19 infections throughout
201 the pandemic [27]. Our findings corroborate with this and highlight the importance of incorporating
202 racial and social factors in screening for COVID-19 infection.

203 Our study has several limitations. First, our data contained sampling and ascertainment bias
204 since SARS-CoV-2 testing was based on symptom presentation. We did not test children at random,
205 rather we tested children based on the presence of certain symptoms, which were pre-determined by
206 our testing algorithms at that time. Initially, these symptoms included only fever and respiratory
207 symptoms. Diarrhea and loss of taste/smell were added late in the study period, which likely explains
208 the observed lower prevalence of those symptoms in our study population. Second, we assessed
209 patient encounters that occurred during the early months of the pandemic. Data on COVID-19
210 symptoms were just beginning to emerge at that time, which may have played a role in symptom
211 documentation and triage. Third, our study was limited to hospitals that are situated in urban settings
212 in a single state, which limits generalizability. Finally, we were not able to assess social and
213 environmental factors such as household structure, parental occupation, and environmental
214 exposures, all of which may influence disease severity and subsequent symptom presentation.

215 As evidence continues to grow, our study provides further insight into COVID-19 symptoms
216 among the pediatric population. However, the presence or absence of any single symptom, other than
217 possibly the sudden loss of taste or smell, is not sufficient to guide clinical decision-making in testing
218 for SARS-CoV-2 among pediatric patients presenting to emergency facilities. When considering
219 testing for COVID-19, clinicians should be attuned to other factors that may predispose patients to
220 increased risk, such as social determinants of health and patients' social habits. Additionally, given
221 that COVID-19 infectivity is growing in the pediatric population with the addition of newer variants
222 as compared to the start of the pandemic, it is essential that clinicians maintain a low threshold for
223 testing children with a variety of symptoms, allowing for improved disease detection and aiding the
224 prevention of subsequent spread.

225

226

227

228

229

230

231

Correlation of Suspected COVID-19 Symptoms with COVID-19 Positivity in Children

232 5 Tables

233 **Table 1.** Patient Characteristics of those tested for COVID-19. *Note.* NH = non-Hispanic, ADI = area
 234 deprivation index. The ^ap-value is a comparison of patient characteristics between children who
 235 tested positive versus children who tested negative for COVID-19. For continuous variables, means
 236 are compared with *t* tests. For categorical variables, proportions are compared with chi-square tests

Characteristics	Tested (n = 516)	Positive (n = 46)	Negative (n = 470)	^a p-value
Total	516 (100.0%)	46 (8.9%)	470 (91.1%)	<0.001
Age (SD)	6.64 (5.84)	8.76 (6.38)	6.43 (5.75)	0.01
Age category				
0-13 months	137 (26.6%)	10 (21.7%)	127 (27.0%)	0.008
13 mos-4 years	129 (25.0%)	5 (10.9%)	124 (26.4%)	
5-11 years	107 (20.7%)	9 (19.6%)	98 (20.9%)	
12-17 years	143 (27.7%)	22 (47.8%)	121 (25.7%)	
Female sex	262 (50.8%)	25 (54.4%)	237 (50.4%)	0.61
Race/Ethnicity				
NH White	149 (28.9%)	6 (13.0%)	143 (30.4%)	<.0001
NH Black	171 (33.1%)	6 (13.0%)	165 (35.1%)	
Hispanic	111 (21.5%)	27 (58.7%)	84 (17.9%)	
Asian	45 (8.7%)	3 (6.5%)	42 (8.9%)	
Other/Unknown	40 (7.8%)	4 (8.7%)	36 (7.7%)	
Insurance				
Public	261 (50.6%)	24 (52.2%)	237 (50.4%)	<0.001
Private	208 (40.3%)	7 (15.2%)	201 (42.8%)	
Other	24 (4.7%)	8 (17.3%)	16 (3.4%)	
Uninsured	23 (4.5%)	7 (15.2%)	16 (3.4%)	
Mean ADI	5.13 (2.82)	5.65 (2.86)	5.08 (2.82)	0.19

237

238

239

240

241

Correlation of Suspected COVID-19 Symptoms with COVID-19 Positivity in Children

242 **Table 2.** Symptom Complaints of those tested for COVID-19. The ^ap-value is a comparison of
 243 symptoms between children who tested positive versus children who tested negative for COVID-19.
 244 For categorical variables, proportions are compared with chi-square tests

Symptoms	Positive COVID test (n= 46)	Negative COVID test (n= 470)	^a p-value
History of Fever	36 (78.3%)	287 (61.1%)	0.05
Headache	11 (23.9%)	56 (11.9%)	0.06
Sore throat	8 (17.4%)	50 (10.6%)	0.30
Cough	24 (52.2%)	223 (47.4%)	0.44
Shortness of Breath	9 (19.6%)	76 (16.2%)	0.70
Myalgia	10 (21.7%)	28 (6.0%)	0.001
Diarrhea	2 (4.3%)	56 (11.9%)	0.25
Loss of taste or smell	7 (15.2%)	4 (0.9%)	<0.001

245

246 **6 Conflict of Interest**

247 *The authors declare that the research was conducted in the absence of any commercial or financial*
 248 *relationships that could be construed as a potential conflict of interest.*

249 **7 Author Contributions**

250 SS conceptualized and designed the study, analyzed, and interpreted the data, drafted the manuscript,
 251 and critically revised the manuscript for intellectual content.

252 DH, AH, LP, OB, and AK conceptualized and designed the study, acquired, analyzed, and interpreted
 253 the data, critically revised the manuscript for intellectual content, provided administrative, technical,
 254 and material support for the study, and provided overall study supervision.

255 All authors read and approved the final manuscript.

256 **8 Funding**

257 This project was funded by the Emergency Medicine Foundation COVID-19 Research Grant

258 **9 References**

- 259 1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard (2021).
 260 <https://covid19.who.int>. Accessed October 24, 2021.
- 261 2. Centers for Disease Control and Prevention. Information for Pediatric Healthcare Providers
 262 (2020). <https://www.cdc.gov/coronavirus/2019-ncov/hcp/pediatric-hcp.html>. Accessed
 263 October 24, 2021.
- 264 3. Girona-Alarcon M, Bobillo-Perez S, Sole-Ribalta A, Hernandez L, Guitart C, Suarez R, et.al.
 265 The different manifestations of COVID-19 in adults and children: a cohort study in an
 266 intensive care unit. *BMC Infect Dis.* 2021; 21,87. doi: 10.1186/s12879-021-05786-5

Correlation of Suspected COVID-19 Symptoms with COVID-19 Positivity in Children

- 267 4. Dhochak N, Singhal T, Kabra SK, Lodha R. Pathophysiology of COVID-19: Why Children
268 Fare Better than Adults. *Indian J Pediatr.* 2020; 1-10. doi: 10.1007/s12098-020-03322-y
- 269 5. Healthline. How COVID-19 Affects Children Compared to Adults (2020).
270 <https://www.healthline.com/health-news/how-covid-19-affects-children-compared-to-adults>.
271 Accessed October 24, 2021.
- 272 6. Du W, Yu J, Wang H, Zhang X, Zhang S, Li Q, et.al. Clinical characteristics of COVID-19 in
273 children compared with adults in Shandong Province, China. *Infection.* 2020; 1-8. doi:
274 10.1007/s15010-020-01427-2
- 275 7. DeBiasis RL, Song X, Delaney M, Bell M, Smith K, Pershad J, et.al. Severe Coronavirus
276 Disease-2019 in Children and Young Adults in the Washington, DC, Metropolitan Region. *J*
277 *Pediatr.* 2020; 223:199-203. doi: 10.1016/j.jpeds.2020.05.007
- 278 8. Belhadjer Z, Meot M, Bajolle F, Khraiche D, Legendre A, Abakka S, et.al. Acute Heart
279 Failure in Multisystem Inflammatory Syndrome in Children in the Context of Global SARS-
280 CoV-2 Pandemic. *Circulation.* 2020; 142(5). doi: 10.1161/CIRCULATIONAHA.120.048360
- 281 9. Centers for Disease Control and Prevention. For Parents: Multisystem Inflammatory
282 Syndrome in Children (MIS-C) associated with COVID-19 (2021).
283 <https://www.cdc.gov/mis/mis-c.html>. Accessed October 24, 2021.
- 284 10. Hennon TR, Penque MD, Abdul-Aziz R, Alibrahim OS, McGreevy MB, Prout AJ, et.al.
285 COVID-19 associated Multisystem Inflammatory Syndrome in Children (MIS-C) guidelines;
286 a Western New York approach. *Prog Pediatr Cardiol.* 2020; 101232. doi:
287 10.1016/j.ppedcard.2020.101232
- 288 11. Jiang L, Tang, K, Levin M, Irfan O, Morris SK, Wilson K, et.al. COVID-19 and multisystem
289 inflammatory syndrome in children and adolescents. *Lancet Infect Dis.* 2020; 20(11):e276-
290 e288. doi: 10.1016/S1473-3099(20)30651-4
- 291 12. Hodgson LE, Leckie T, Hunter A, Prinsloo N, Venn R, Forni L. COVID-19 recognition and
292 digital risk stratification. *Future Healthc J.* 2020; 7(3):e47-e49. Doi: 10.7861/fhj.2020-0037
- 293 13. Ma J, Shi X, Xu W, Ly F, Wu J, Pan Q, et.al. Development and validation of a risk
294 stratification model for screening suspected cases of COVID-119 in China. *Aging.* 2020;
295 12(14):13882-13894. doi: 10.18632/aging.103694
- 296 14. Jarrett J, Uhteg K, Forman MS, Hanlon A, Vargas C, Carroll KC, et.al. Clinical performance
297 of the GenMark Dx ePlex respiratory pathogen panels for upper and lower respiratory tract
298 infections. *J Clin Virol.* 2021; 135:104737.
- 299 15. Mostafa HH, Carroll KC, Hicken R, Berry GJ, Manji R, Smith E, et.al. Multi-center
300 Evaluation of the Cepheid Xpert® Xpress SARS-CoV-2/Flu/RSV Test. *J Clin Microbiol.*
301 2020; doi:10.1128/JCM.02955-20.
- 302 16. Mostafa HH, Hardick J, Morehead E, Miller JA, Gaydos CA, Manabe YC. Comparison of the
303 analytical sensitivity of seven commonly used commercial SARS-CoV-2 automated
304 molecular assays. *J Clin Virol.* 2020; 130:104578
- 305 17. Uhteg K, Jarrett J, Richards M, Howard C, Morehead E, Geahr M, et.al. Comparing the
306 analytical performance of three SARS-CoV-2 molecular diagnostic assays. *J Clin Virol.*
307 2020; 127:104384
- 308 18. Johns Hopkins Institute for Clinical and Translational Research. Precision Medicine
309 Analytics Platform (PMAP). [https://ictr.johnshopkins.edu/programs_resources/programs-](https://ictr.johnshopkins.edu/programs_resources/programs-resources/i2c/pmap/)
310 [resources/i2c/pmap/](https://ictr.johnshopkins.edu/programs_resources/programs-resources/i2c/pmap/). Accessed October 24, 2021.
- 311 19. AAP. Children and COVID-19: State-Level Data Report (2022).
312 [https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-](https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/)
313 [covid-19-state-level-data-report/](https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-state-level-data-report/). Accessed January 16, 2022.
- 314 20. Jones, J. Epidemiology of COVID-19 in Children Aged 5-11 years. Epidemiology Task Force
315 CDC COVID-19 Public Health Response. 2021. Available online at:

Correlation of Suspected COVID-19 Symptoms with COVID-19 Positivity in Children

- 316 [https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-11-2-3/03-COVID-
318 Jefferson-508.pdf](https://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-11-2-3/03-COVID-
317 Jefferson-508.pdf).
- 319 21. NBC. Hospital are experiencing supply shortages for COVID tests.
320 [https://www.nbcrightnow.com/national/some-hospitals-are-experiencing-supply-shortages-
322 for-covid-tests/article_2f24b7de-740e-11ec-b5f3-bfdb6400f2d.html](https://www.nbcrightnow.com/national/some-hospitals-are-experiencing-supply-shortages-
321 for-covid-tests/article_2f24b7de-740e-11ec-b5f3-bfdb6400f2d.html). Accessed January 16,
323 2022
- 324 22. Lamb MR, Kandula S, Shaman J. Differential COVID-19 case positivity in New York City
325 neighborhoods: Socioeconomic factors and mobility. *Influenza Other Respi Viruses*. 2021;
326 15:209-217.
- 327 23. Acevedo-Garcia D, Noelke C, McArdle N, Sofer N, Hardy EF, Weiner M, Baek M, et.al.
328 Racial And Ethnic Inequities In Children’s Neighborhoods: Evidence From The New Child
329 Opportunity Index 2.0. *Health Aff*. 2020; 39(10):1693-1701. doi: 10.1377/hlthaff.2020.00735
- 330 24. Johns Hopkins Medicine. The Johns Hopkins Hospital Fiscal Year 2017 Community Benefits
331 Report Narrative. [https://web.jhu.edu/administration/gca/projects/publications-and-
333 reports/CBR%20Reports/CBR%202017/FY%202017%20JHH%20CBR%20Report.pdf](https://web.jhu.edu/administration/gca/projects/publications-and-
332 reports/CBR%20Reports/CBR%202017/FY%202017%20JHH%20CBR%20Report.pdf).
334 Accessed November 19, 2021.
- 335 25. Gershengorn HB, Patel S, Shukla B, Warde PR, Bhatia M, Parekh D, et.al. Association of
336 Race and Ethnicity with COVID-19 Test Positivity and Hospitalization Is Mediated by
337 Socioeconomic Factors. *Ann Am Thorac Soc*. 2021; 18(8): 1326-1334.
- 338 26. AAP News. Study: Hispanic, Black, low-income children had highest rates of SARS-CoV-2
339 2020. <https://www.aappublications.org/news/2020/08/05/covid19disparities080520>. Accessed
340 October 30, 2021.
- 341 27. Muñoz-Price LS, Nattinger AB, Rivera F, Hanson R, Gmehlin CG, Perez A, Singh S, Buchan
342 BW, Ledebner NA, Pezzin LE. Racial Disparities in Incidence and Outcomes Among Patients
343 with COVID-19. *JAMA Netw Open*. 2020;3(9), e2021892.
- 344 28. Feketea GM, Vlacha V. A Decision-Making Algorithm for Children With Suspected
345 Coronavirus Disease 2019. *JAMA Pediatr*. 2020; 174(12):1220-1222. Doi:
346 10.1001/jamapediatrics.2020.2999
- 347 29. Johns Hopkins Medicine. COVID in Babies and Kids: Symptoms and Prevention.
348 [https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/coronavirus-in-
350 babies-and-children](https://www.hopkinsmedicine.org/health/conditions-and-diseases/coronavirus/coronavirus-in-
349 babies-and-children). Accessed October 24, 2021.
- 351 30. Teherani MF, Kao CM, Camacho-Gonzalez A, Banskota S, Shane AL, Linam WM, Jaggi P.
352 Burden of Illness in Households With Severe Acute Respiratory Syndrome Coronavirus 2-
353 Infected Children. *Journal of Pediatric Infectious Diseases Society*. 2020; 9(5),613-616.
- 354 31. Viner RM, Ward JL, Hudson LD, Ashe M, Patel SV, Hargreaves D, Whittaker E. Systematic
355 review of reviews of symptoms and signs of COVID-19 in children and adolescents. *Archives
356 of Disease in Childhood*. 2021; 106:802-807.
- 357 32. Pahwa R, Goyal A, Bansal P, Jialal I. “Chronic Inflammation”. In: StatPearls. Treasure
358 Island, FL: StatPearls Publishing LLC. 2019.
- 359 33. Habibzadeh P, Mofatteh M, Silawi M, Ghavami S, Faghihi MA. Molecular diagnostic assays
360 for COVID-19: an overview. *Crit Rev Clin Lab Sci*. 2021; Sep;58(6):385-398. doi:
10.1080/10408363.2021.1884640. Epub 2021 Feb 17. PMID: 33595397; PMCID:
PMC7898297

Correlation of Suspected COVID-19 Symptoms with COVID-19 Positivity in Children

361 **10 Abbreviations**

362 US = United States

363 ED = emergency department

364 COVID-19 = coronavirus disease 2019

365 SARS-CoV-2 = severe acute respiratory syndrome coronavirus 2

366 MIS-C = multisystem inflammatory syndrome in children

367 ILI = influenza-like illness

368 PMAP = Precision Medicine Analytics Data Commons Platform

369 ESI = emergency severity index

370 ADI = area deprivation index

371 EMR = electronic medical record

372 GI = gastrointestinal

373 ILI = influenza-like illness

374 **11 Data Availability Statement**

375 The dataset generated and analyzed for this study can be obtained from the corresponding authors
376 upon request.